EUVIMEDEUVIMED entdecken
Validierungsstudie

Clinical validation of preoperative serum markers for liver fibrosis in living donor liver transplantation recipients

Takahiro Tomino, Shinji Itoh, Takeo Toshima, Shohei Yoshiya, Yuki Bekki, Norifumi Iseda, Takuma Izumi, Yuriko Tsutsui, Katsuya Toshida, Tomoharu Yoshizumi

Surgery Today · 2025

DOI: 10.1007/s00595-024-02941-8 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Surgery Today, 2025. Verfasst von Takahiro Tomino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. Hauptthemen laut MEDLINE: Liver Transplantation, Liver Cirrhosis, Living Donors, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To validate the reliability of fibrosis markers as predictors of graft survival in living donor liver transplantation (LDLT) recipients. METHODS: We reviewed data retrospectively, from 163 patients who underwent adult LDLT with preoperative measurements of type IV collagen (CIV), Mac-2 binding protein glycosylation isomer (M2BPGi), and hyaluronic acid (HA). Patients were divided into high and low groups for each biomarker, based on optimal cutoff values, and graft loss within 6 months was evaluated in each group. RESULTS: The high CIV level group showed significantly lower 6-month graft survival rates and significantly higher rates of postoperative sepsis and sepsis from pneumonia. However, the groups with high and low M2BPGi levels and those with high and low HA levels did not show significant differences in 6-month graft survival rates or rates of postoperative sepsis. Multivariate analysis revealed that a CIV level ≥ 590 was a significant predictor of graft loss within 6 months, postoperative sepsis, and sepsis from pneumonia. CONCLUSION: Unlike other fibrosis markers, preoperative CIV levels can predict graft survival, postoperative sepsis, and sepsis from pneumonia after LDLT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationLiver CirrhosisLiving DonorsBiomarkersGraft SurvivalHyaluronic AcidCollagen Type IVHumansMaleFemaleMiddle AgedRetrospective StudiesAdultPreoperative PeriodSepsisPostoperative ComplicationsAgedPneumoniaReproducibility of Results

Stichwörter der Autor:innen

Hyaluronic acidLiver transplantationMac-2 binding protein glycosylation isomerSepsisType IV collagen

Substanzen

BiomarkersHyaluronic AcidCollagen Type IV

Autor:innen und Institutionen

  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. itoh.shinji.453@m.kyushu-u.ac.jp.

Zitieren

APA

Tomino, T., Itoh, S., Toshima, T., Yoshiya, S., Bekki, Y., Iseda, N., Izumi, T., Tsutsui, Y., Toshida, K., & Yoshizumi, T. (2025). Clinical validation of preoperative serum markers for liver fibrosis in living donor liver transplantation recipients. Surgery Today. https://doi.org/10.1007/s00595-024-02941-8

Vancouver

Tomino T, Itoh S, Toshima T, Yoshiya S, Bekki Y, Iseda N, et al. Clinical validation of preoperative serum markers for liver fibrosis in living donor liver transplantation recipients. Surgery Today. 2025. doi:10.1007/s00595-024-02941-8

BibTeX
@article{Tomino2025,
  author = {Tomino, Takahiro and Itoh, Shinji and Toshima, Takeo and Yoshiya, Shohei and Bekki, Yuki and Iseda, Norifumi and Izumi, Takuma and Tsutsui, Yuriko and Toshida, Katsuya and Yoshizumi, Tomoharu},
  title = {Clinical validation of preoperative serum markers for liver fibrosis in living donor liver transplantation recipients},
  journal = {Surgery Today},
  year = {2025},
  doi = {10.1007/s00595-024-02941-8}
}
Kostenlos starten →